SHANGHAI – For some pharma executives parachuting into China it may come as a surprise to learn that the best way to get rid of a corrupt employee is to pay them off. Read More
SHANGHAI – Last week the CFDA put out a circular to warn Chinese consumers about the dangers of buying cancer medicines online, in particular drugs that claim to be Iressa (gefitinib) imported from India. Read More
Ruiyi Inc. and the Ihuman Institute forged a research collaboration allowing the upstart educational institution, housed at China's Shanghaitech University, to apply the company's intermembranous conformation antigen presenting system, or iCAPS, technology for the creation of monoclonal antibodies (MAb) that specifically bind to G protein-coupled receptors (GPCR). The goal of the program is to investigate the biological function and structure of GPCRs. Read More
TOKYO – Representatives of various U.S. organizations are urging Japan to reconsider a proposal that would revise reimbursement prices for pharmaceuticals on an annual, rather than a biennial, basis. Read More
SHANGHAI – While Wuxi Apptec may be best known for its biologic manufacturing capabilities, it could be overlooked that the firm has ratcheted up its capabilities in clinical drug development as well. Read More
SHANGHAI – China's distribution sector took a big step toward consolidation with the announcement that Sinopharm Group Co. Ltd. and Shanghai Fosun Group Co. Ltd. would form a joint venture (JV) to create what promises to be the first nationwide drug and medical device network. Read More
HONG KONG – Looking to reach out to more users and drug companies and riding the wave of growth of online information and platforms to facilitate the sharing of information between governments and users, China's drug regulator is now using mobile technology as part of its communications strategy. Read More
Senju Pharmaceutical Co. Ltd., of Osaka, Japan, will pay Alameda, Calif.-based Insite Vision Inc. an undisclosed amount for the right to develop and market ocular antibiotics incorporating Insite's Durasite drug delivery platfom in Japan. The deal includes an up-front license fee, additional development milestones fees and a percentage royalty on net sales. Read More
